Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Slower magnesium drip may help sickest patients hold onto the mineral

NCT ID NCT01426165

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 10, 2026 · Last updated Sep 11, 2026 · Updated 1 time

Summary

Critically ill patients often have low magnesium, which can lead to heart rhythm problems and other complications. When magnesium is given through an IV, the body keeps only about half of it. Researchers are testing whether giving the same dose over 8 hours instead of 4 hours helps patients retain more magnesium. The study enrolls adults in a medical intensive care unit who have low magnesium and need IV replacement.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
magnesium sulfate given intravenously
What this could lead to
If slower infusions help the body hold onto more magnesium, doctors could adjust how they give this common mineral to critically ill patients with low levels.
What could go wrong
This is a very small study of five patients in one hospital, so its results may not apply broadly. Magnesium infusions can affect heart rhythm and kidney function, and patients with kidney problems are excluded.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

5 people

The number who actually took part.

Started

Apr 2011

Finished

Dec 2012

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Medicine ICU service patients * \> 18 years old with * hypomagnesemia defined by a serum magnesium level \< 2 mg/dL and the clinical decision by the rounding team to replace with parenteral magnesium sulfate * must have an available IV line for magnesium infusion that may be used for up to 8 hours * must have a Foley catheter Exclusion Criteria: * renal dysfunction defined by an estimated creatinine clearance (CrCl) \< 30 mL/min or have had an average of \< 0.5 mL/kg/hr of urine output over the previous 12 hours before the magnesium infusion is to begin * Subjects must not have received a loop diuretic within the 12 hours prior to magnesium replacement and will further be excluded if they receive these medications during the magnesium replacement and urine collection time period * Subjects with ostomies or acute diarrhea will be excluded due to the possibility of high gastrointestinal magnesium loss * Subjects will be excluded if they have a physician order for magnesium sulfate to be infused over a specified time period * If subjects are expected to be moved out of the ICU within the next 24 hours, they will not be considered for randomization due to potential lack of appropriate urine magnesium collection and follow up * Each subject may only be enrolled in the study for one occurrence of hypomagnesemia

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Primary hypomagnesemia (disorder) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Charleston Area Medical Center

    Charleston, West Virginia, 25301, United States